SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Telix Pharmaceuticals Limited (TLPPF) , forward earnings yield 0.52%. PEG 1.73.
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 192.7
- PEG Ratio 1.73 — between 1.0–2.0 indicates moderate valuation relative to growth.
Overall SharesGrow Score: 50/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TLPPF
Valuation Multiples
P/E (TTM)0.0
Forward P/E192.7
PEG Ratio1.73
Forward PEG1.73
P/B Ratio0.00
P/S Ratio2.85
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.03
Forward EPS (Est.)$0.05
Book Value / Share$0.00
Revenue / Share$3.69
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.52%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.00 |
$0.00 |
$-44K |
- |
| 2017 |
$-0.05 |
$0.00 |
$-6.38M |
- |
| 2018 |
$-0.07 |
$195.14K |
$-13.83M |
-7087.1% |
| 2019 |
$-0.12 |
$3.49M |
$-27.87M |
-799.6% |
| 2020 |
$-0.17 |
$5.21M |
$-44.89M |
-861.1% |
| 2021 |
$-0.29 |
$7.6M |
$-80.51M |
-1059.9% |
| 2022 |
$-0.34 |
$160.1M |
$-104.08M |
-65% |
| 2023 |
$0.02 |
$502.55M |
$5.21M |
1% |
| 2024 |
$0.14 |
$783.21M |
$49.92M |
6.4% |
| 2025 |
$-0.03 |
$1.25B |
$-11.05M |
-0.9% |
